Shinya Yamanaka


I was born on September 4, 1962, in Osaka, Japan. My father, Shozaburo, ran a small factory in the city of Higashi-Osaka manufacturing components for sawing machines, which he took over in his early 20s after my grandfather passed away. Higashi-Osaka is well known for its cluster of highly skilled small and midsize manufacturers. Like other owners of small companies in the area, my father was an engineer who designed new products and made them by himself. My mother, Minako, helped him run the business, raising their two children, me and my older sister, Yumiko. Looking back on my childhood, I can see now that my father exerted a great influence on me. He did not force me to do or be anything, but, by showing diligence in his work, he taught me silently how meaningful it is to create something from the drawing board, and how interesting it is to seek for oneself a better way of achieving a goal.

I remember that when I was a child, I found it very exciting to dismantle clocks and radios into small pieces and then try to assemble them again, though most of the time I ended up breaking them. Maybe I just copied what my father was doing. My childhood dream was to become an engineer like him. Science was one of my favorite classes at school. I liked reading a monthly scientific magazine for elementary school children. This magazine came with various kits for children to do experiments. I remember one time I was doing an experiment with an alcohol lamp that came with the magazine. It dropped onto a kotatsu heater table and the quilt over it caught fire. I was severely scolded by my mother.

I was educated at the Tennoji Junior High School/High School attached to Osaka Kyoiku University and received an excellent education, with many unique friends and teachers. Entering the junior high in 1975, I joined its judo team as my father recommended me. He thought I was too skinny and should become stronger. I devoted myself to judo and continued practicing it for several years until I quit it due to a serious injury in my second year at college. At the high school, there were some teachers who often told students that we should try to become a superman or superwoman, meaning that we should not only study hard but also try to experience many activities such as sports and activities in the student association. Inspired by them, I formed a folk song band with my classmates, called “Karesansui” (‘Dry Garden Style’), and performed at the school’s student festivals. I played the guitar and was a vocalist. I also committed to the school association as a vice president.

Throughout my school years, I was good at mathematics and physics. Thinking about my career, I considered studying basic sciences in college but decided to go to medical school, partly because my father used to advise me to become a physician instead of taking over his business. I don’t know why that was his wish, but he may have thought that I was not cut out for business or may have wanted me to have a job more stable than running a small business that is easily affected by the economic climate. A book also pushed me to become a medical doctor. I was deeply inspired by Torao Tokuda, a physician who founded a hospital group in the 1970s that tried to revolutionize the Japanese medical care system. In 1981, I succeeded in my ambition of being accepted at Kobe University’s School of Medicine. There again, I enjoyed playing judo and rugby, and suffered many broken bones while doing sports. In addition, I often suffered from severe pain in my legs due to over-training. These experiences made me interested in sports medicine and I decided to become an orthopedic surgeon.

After receiving an M.D. from Kobe University in 1987, I served as a resident at the Osaka National Hospital for two years. During this period, two major events happened to me. I married Chika, whom I first met as a classmate at junior high school. She became a dermatologist and now runs a clinic in Osaka. The other unforgettable event was my father’s death. He had long suffered from diabetes and also had hepatitis caused by a blood transfusion he had received a few years earlier to treat an injury. During his last two years, as a medical student and resident I gave him injections and administered intravenous drips, and he seemed happy to receive such treatments from his son.

Working at the hospital, I found that my surgical skills were not as good as I expected. One time it took me two hours to do a surgical operation which could have been completed in 30 minutes by other surgeons. My supervisors were very tough on new residents like me, and I lost confidence in my ability. In addition, treating many patients with intractable diseases and injuries such as rheumatoid arthritis and spinal cord injury, I realized that there were many diseases that even talented surgeons and physicians cannot cure. Even now, I recall clearly one female patient who had severe rheumatoid arthritis. There was a photograph of a cheerful woman on her bedside cabinet. I though it must be her sister or something. Learning that it was herself only a few years back, I was shocked that the patient looked totally different because of the disease. Painful and unforgettable bedside experiences finally drove me to switch my goal from becoming a surgeon who would help free patients from pain to becoming a basic scientist who would eradicate those intractable diseases by finding out their mechanisms and ultimately a way of curing them.

As the first step toward my new goal, I became a Ph.D. student in pharmacology at Osaka City University Graduate School of Medicine in 1989, working in Kenjiro Yamamoto’s laboratory. During the next four years, I learned the essentials about how to design and conduct experiments and analyze data from my direct mentor, Katsuyuki Miura. The first instruction he gave me was to read as many papers as possible to help me think about a research theme. A few months later he assigned me to perform an experiment to study the role of a blood lipid named platelet-activating factor in lowering blood pressure in dogs. Miura’s hypothesis was that administering an inhibitor of another lipid, thromboxane A2, which is activated by platelet-activating factor, would prevent the blood pressure from going down. But my experiment showed a completely opposite result. I was so excited with the unexpected outcome that I became totally fascinated by basic science. Miura was also enthusiastic about the findings even though they were against his hypothesis. This study later became my Ph.D. dissertation, published in Circulation Research in 1993. There was an eye-opening moment when Miura told me that scientists have to compete with researchers around the  world. When I was a resident, my rivals were other residents at the same hospital. As a scientist, I could win global recognition in a scientific field, albeit a small one, if my findings were published in high-profile journals. His words made me pay keen attention to research abroad.

At the time, I was astonished by mouse transgenesis and gene targeting, which specifically induce or delete a single gene of interest, because no pharmacological agents could perform such miracles. After finishing my Ph.D. work in 1993, I applied for as many postdoctoral positions as I could in labs doing mouse molecular genetics because I wanted to obtain postdoctoral training and further skills including techniques to make knockout mice. However, it was very natural that a failed surgeon with little experience in molecular biology had a hard time finding a position. A turning point came when I got a fax from Thomas Innerarity at the Gladstone Institute of Cardiovascular Diseases in San Francisco. After a short telephone conversation, Tom was brave enough to give me a postdoctoral position in his lab! Working at Gladstone was one of the best decisions I ever made in my life. Gladstone provided an almost perfect environment for an ambitious new researcher like me thanks to its skillful technicians and the provocative discussions about science I had with enthusiastic colleagues.

When I joined Tom’s lab, he had a hypothesis that forced expression in the liver of APOBEC1, the ApoB messenger RNA-editing enzyme, would lower plasma cholesterol levels and thus prevent atherosclerosis. To examine this hypothesis, I generated transgenic mice overexpressing Apobec1 in their livers. To our surprise, however, the transgenic mice developed liver tumors. We learned that Apobec1 is a potent protooncogene. Naturally, Tom was disappointed, but I became very interested in the molecular mechanisms of this totally unexpected result. Tom, despite the finding being against his hypothesis, encouraged me to continue studying the APOBEC1-mediated oncogenesis. Thanks to his support, I identified a novel target of Apobec1, Nat1, which was aberrantly edited in the transgenic mouse livers. I decided to generate Nat1-knockout mice to study the gene’s function. Robert Farese at Gladstone and his research associate Heather Myers kindly taught me how to culture mouse embryonic stem (ES) cells and make chimeras.

Gladstone also provided me with the opportunity to acquire presentation skills and to learn a key idea for success as a scientist. One day, Robert Mahley, the then president of Gladstone, gathered about 20 postdocs and said that “VW” was a magic word to make us successful scientists. What he meant was that scientists need to have a clear vision and work hard toward it. I found myself not having a clear vision, although I was confident that I was one of the most hard-working postdocs at Gladstone at the time. I have since set my vision as being “to contribute to the development of new cures for patients through basic research.” I still have the “VW” lesson in mind and often quote it to my students in my lab.

In 1996, my wife Chika and our two daughters, Mika and Miki, who were living in San Francisco with me, returned to Japan to enroll Mika in an elementary school in Osaka. About six months after they left, I went back to Japan as I missed them so much. Back in my home country, I eventually got an assistant professor position in the department of pharmacology at Osaka City University Medical School. Tom kindly let me continue the Nat1 work and shipped three chimeric mice I had made to Japan. The then chairman of the department, Hiroshi Iwao, was very supportive and allowed me to work on Nat1, which seemed to have little value in pharmacology. I found that Nat1 is required for early mouse development. More importantly, I found that Nat1-null embryonic stem (ES) cells proliferate normally but cannot properly differentiate. These surprising findings changed the meaning of mouse ES cells for me from a research tool to a research subject. I became intrigued in how ES cells maintain their differentiation ability while rapidly proliferating.

In Japan, however, I found myself suffering from Post America Depression or PAD. The environment for researchers in Japan was quite different in many ways from that in the U.S. At the medical school, very few scientists showed interest in the basic biology of mouse ES cells, and there was little thought-provoking discussion with my colleagues. Some  of  my  colleagues  advised  me  to  work on something more related to medicine. Furthermore, I could not get enough funding and had to change the cages of the numerous mice by myself every week. What was worse, the Nat1 work was being rejected by many journals. I felt lonely and depressed, and I was about to give up my career as a scientist and return to the path of physician.

Fortunately, two events rescued me from PAD and from giving up on science. First, James Thomson of the University of Wisconsin-Madison and his colleagues announced that they had succeeded in  generating  human  ES cells in 1998. His success taught me that ES cells have enormous potential in medicine and encouraged me to continue my research. Second, in December 1999, I got a new position as an associate professor with my own laboratory for the first time in my career at the Nara Institute of Science and Technology (NAIST ) in Nara Prefecture. This institute has brilliant investigators in basic and applied sciences, an excellent research environment and competent Ph.D. students. I was fortunate that several talented colleagues and students joined my laboratory.

At NAIST, I was expected to establish a knockout mouse core facility. It was a difficult task, but thanks to an excellent technician, Tomoko Ichisaka, and to funding from NAIST, we were able to establish it within a few years. The first gene that we knocked out was Fbxo15, which we identified as a gene specifically expressed in mouse ES cells. One of my first Ph.D. students, Yoshimi Tokuzawa, with the help of Tomoko, successfully targeted the gene. However, we did not see any phenotypes in mice or ES cells lacking Fbxo15. We were disappointed, but this knockout mouse line turned out later to be useful in the generation of induced pluripotent stem cells or iPS cells.

As a principal investigator, I needed to set a long-term goal for my laboratory. Because of my interest in ES cells, because of the successful generation of human ES cells and because I had to use ES cells anyway in the knockout mouse core facility, I decided to list “ES cells” in the title of my lab website. At the time, most researchers focused on differentiating from ES cells into somatic cells. Human ES cells are associated with two major hurdles – ethical issues regarding the use of human embryos and immune rejection after they are transplanted into a human body. The use of human embryos has been an obstacle to the promotion of ES cell research in many countries, including the U.S. and Japan. To overcome these major hurdles, I decided nuclear reprogramming would be the goal of my lab. More precisely, I set my lab’s goal as being to generate ES cell-like pluripotent cells from somatic cells, without using embryos.

Nuclear reprogramming was first proved by Sir John Gurdon in 1962, the year I was born. He reported the generation of new frogs by transferring tadpole intestine cell nuclei into enucleated eggs from the African clawed toad, Xenopuslaevis. Then, in 1997, Sir Ian Wilmut’s team unveiled Dolly the sheep, the first cloned mammal created using a nuclear transfer method. These achievements showed that the genome DNA of mature cells theoretically have all the information needed to develop animals. A further advance came in a 2001 report by Takashi Tada of Kyoto University, who demonstrated that thymocytes acquire pluripotency upon electrofusion with mouse ES cells, which indicated that ES cells also contain factors that induce pluripotency in somatic cells. However, I knew that making pluripotent cells from somatic cells would be extremely difficult, and when I started this project with my lab members at NAIST, I was not sure if the goal could be achieved in my lifetime.

My initial hypothesis was that factors that maintain the pluripotency of mouse ES cells might induce pluripotency in somatic cells. With the great help of the initial members of my lab – Tomoko, Yoshimi, and two other students, Kazutoshi Takahashi and Eiko Kaiho, and then Assistant Professor Kaoru Mitsui, my lab identified many factors that either are specifically expressed by or have important roles in mouse ES cells. Among them was the transcription factor Klf4, identified by Yoshimi. By 2004, with our own work and that of other groups, we had collected 24 initial candidate genes that might be able to induce pluripotency in somatic cells. We then needed a simple and sensitive assay system to evaluate these candidates, and the Fbxo15-knockout mice turned out to be such a system. Instead of simply deleting the gene, we knocked the neomycin resistant gene (neoR) into the Fbxo15 locus. Somatic cells derived from these mice do not express neoR and are sensitive to the antibiotic G418. Somatic cells that become ES cell–like pluripotent cells after transfection with some of our candidate genes should express neoR and become resistant to G418.

In 2004, I moved to the Institute of Frontier Medical Sciences at Kyoto University as a professor. The major reason for the change was that I wanted to conduct experiments using human ES cells. NAIST did not have a medical school and a hospital attached, and therefore had no institutional review board to examine a study plan using human ES cells. At that time, Kyoto University was the only institute in Japan that had succeeded in culturing human ES cells. I came to Kyoto with the 24 candidate genes, the Fbxo15-neoR knock-in mice and many members of my lab, including Tomoko and Kazutoshi. I asked Kazutoshi to test the 24 candidates using the Fbxo15 knock-in mice. He was pleased to take over this very risky project and did a remarkable job. When Kazutoshi introduced each candidate into the Fbxo15-neoR reporter fibroblasts using retroviral vectors, no G418-resistant colonies emerged. However, when he introduced the mixture of all 24 genes via retroviral vectors, we observed several drug-resistant colonies in a Petri dish. These cells were similar to ES cells in morphology, proliferation and gene expression. When transplanted into nude mice, they formed teratomas containing a variety of tissues from all three germ layers, showing their pluripotency. Among the myriad combinations of the 24 factors, Kazutoshi found that four transcription factors – Oct3/4, Sox2, Klf4 and c-Myc – are essential.

In 2005, we succeeded in generating ES-like cells with the four factors, and I named the resulting cells “induced pluripotent stem cells or iPS cells.” I was anxious about whether they were really the pluripotent cells that we were looking for because the method used to generate the iPS cells was much simpler than I had expected. In addition, after hearing about a big scandal involving a Korean researcher who falsely reported the successful generation of human ES cells by cloning at around that time, I thought we should repeat our experiments to make sure of the result so that no researcher could cast doubt on our findings. In 2006, we published a paper in Cell on the successful generation of mouse iPS cells using the four factors. Some researchers seemed surprised at the finding that only four genes are needed to reprogram somatic cells into the embryonic state. But in the following months, a few labs at MIT and Harvard demonstrated that they had been able to produce mouse iPS cells using our protocol, and an increasing number of researchers have since started working on the new technology.

Right after we generated mouse iPS cells, my team began to work on reprogramming human somatic cells. In November 2007, we reported the generation of human iPS cells from human fibroblasts by introducing the same quartet of genes via viral vectors. On the same day, Thomson’s lab announced in Science that they had also succeeded in making human iPS cells using a different set of four factors – Nanog, Lin28, Oct3/4 and Sox2. I remember that I worked day and night to publish our paper as quickly as possible after I heard a rumor in the summer that a U.S. group had submitted an article on the successful generation of human iPS cells. My lab members continued to improve the induction and selection methods. Keisuke Okita, with the help of Tomoko, succeeded in making iPS cells that are competent for production of adult chimeras and germline transmission. Masato Nakagawa and Michiyo Koyanagi then showed that iPS cells can be generated without c-Myc, an oncogene. Takashi Aoi showed that iPS cells can be generated not only from fibroblasts but also from adult mouse hepatocytes and gastric epithelial cells.

With the ability to differentiate into virtually all types of cell and to grow robustly like ES cells, iPS cells have enormous potential for pharmaceutical and clinical applications. Patient-specific iPS cells can be used to produce disease model cells in which the pathological process can be studied. Thousands of chemicals and natural products can be tested on such cells, some of which we hope will become new effective medicines for intractable diseases.

The Ministry of Education, Sports, Science and Technology of Japan has since supported iPS cell research in cooperation with other government agencies by providing sufficient funding. Encouraged by this support, in January 2008, about two months after we reported the generation of the human iPS cells, Kyoto University founded the Center for iPS  Cell  Research  and  Applications  (CiRA), the world’s first organization solely focusing on iPS cell technology, under the auspices of the Institute for Integrated Cell-Material Sciences (iCeMS). I was appointed as the Director of CiRA. I had given up my career as a physician, but I had found a powerful tool that could help develop new cures for disease. This center is designed not only to progress with basic research to improve fundamental iPS cell technology but also to use the technology in clinical applications. In April 2010, CiRA became independent of iCeMS as a full-fledged institute in a newly opened research building. At the inauguration ceremony for the new CiRA research building, I publicly pledged to achieve four goals over the first ten years:

CiRA’s Goals for the First 10 Years

1. Establish basic iPS cell technology and secure intellectual property.
2. Create an iPS cell stock for clinical use in regenerative medicine.
3. Conduct preclinical and clinical studies on such diseases as Parkinson’s disease, diabetes and blood diseases.
4. Contribute to the development of therapeutic drugs using patient-derived iPS cells.

Since the discovery of human iPS cells, I have seen iPS cell technology advancing at an amazing speed. Owing to its simple and reproducible method, numerous laboratories inside and outside Japan are now working on iPS cell research, and protocols have been developed for direct reprogramming, whereby somatic cells are directly converted into mature cells of a different type. My lab developed a method to generate safer iPS cells without integrating viral vectors into the cell genome, which was one of the major safety concerns. Now CiRA is promoting the iPS cell stock project, in which we make clinical-grade iPS cell lines from blood cells donated by healthy HLA-homozygous individuals. The iPS cell lines will be distributed to other institutes so that they can differentiate them into various types of cell for use in transplantation therapy. Scientists at CiRA have succeeded in recapitulating a number of abnormalities in the cells of patients with such diseases as amyotrophic lateral sclerosis (ALS) and chronic infantile neurologic cutaneous and articular (CINCA) syndrome, which I hope will contribute to development of new therapeutic drugs. I have a small laboratory at Gladstone since I was offered a senior investigator position in 2007 and the lab members are also working hard. Working for Gladstone is a great pleasure for me as it means I can make some contribution to the institute where I received excellent training as a young scientist.

Running CiRA with some 250 staff, I have come to spend less time discussing their data with my colleagues and students, and have been absorbed by my duties as the “chief executive officer” of CiRA, including devising strategies to advance both basic and applied research and to obtain sufficient funding. Anxious about the lack of financial resources for the future to allow us to continue hiring research support staffers, I even ran the full Kyoto Marathon in 2012 to raise online donations from the public. It was hard but helped us raise more than 10 million yen. Now I hope that receiving the Nobel Prize in Physiology or Medicine will consolidate long-term support from the government and the general public for iPS cell research nationwide.

Looking back at my life, I have been very fortunate that I have encountered many talented students and colleagues who have supported and encouraged me on many occasions, including my lab members in the past and the present. In addition to my direct mentors, I also owe much not only to the great scientists who made breakthrough discoveries in biology but also to countless predecessors who have contributed to the development of nuclear reprogramming and stem cell biology. I am deeply thankful to my wife and our two daughters, who have supported my hectic life as a scientist for years. Finally I am grateful to my parents. I was glad that my mother was able to take part in the award ceremony of the 2012 Nobel Prize in Stockholm. My father wanted me to become a physician who helps a lot of patients. Although I gave up my career as a surgeon, I still hope to help people suffering from serious diseases and injuries. With iPS cell technology I will continue to work hard together with my colleagues to achieve this goal as quickly as possible.

From The Nobel Prizes 2012. Published on behalf of The Nobel Foundation by Science History Publications/USA, division Watson Publishing International LLC, Sagamore Beach, 2013

This autobiography/biography was written at the time of the award and later published in the book series Les Prix Nobel/ Nobel Lectures/The Nobel Prizes. The information is sometimes updated with an addendum submitted by the Laureate.

Copyright © The Nobel Foundation 2012

To cite this section
MLA style: Shinya Yamanaka – Biographical. Nobel Prize Outreach AB 2024. Wed. 27 Mar 2024. <>

Back to top Back To Top Takes users back to the top of the page

Nobel Prizes and laureates

Eleven laureates were awarded a Nobel Prize in 2023, for achievements that have conferred the greatest benefit to humankind. Their work and discoveries range from effective mRNA vaccines and attosecond physics to fighting against the oppression of women.

See them all presented here.

Explore prizes and laureates

Look for popular awards and laureates in different fields, and discover the history of the Nobel Prize.